BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wong R, Yuan LY. Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both. World J Hepatol 2024; 16(6): 871-877 [PMID: PMC11212657 DOI: 10.4254/wjh.v16.i6.871]
URL: https://www.wjgnet.com/1948-5182/full/v16/i6/871.htm
Number Citing Articles
1
Yanyan Xuan, Fangfang He, Qing Liu, Dandan Dai, Dingting Wu, Yanmei Shi, Qi Yao. Elevated GGT to HDL ratio as a marker for the risk of NAFLD and liver fibrosisScientific Reports 2025; 15(1) doi: 10.1038/s41598-024-84649-w
2
Carlos Jiménez-Cortegana, Soledad López-Enríquez, Gonzalo Alba, Consuelo Santa-María, Gracia M. Martín-Núñez, Francisco J. Moreno-Ruiz, Sergio Valdés, Sara García-Serrano, Cristina Rodríguez-Díaz, Ailec Ho-Plágaro, María I. Fontalba-Romero, Eduardo García-Fuentes, Lourdes Garrido-Sánchez, Víctor Sánchez-Margalet. The Expression of Genes Related to Reverse Cholesterol Transport and Leptin Receptor Pathways in Peripheral Blood Mononuclear Cells Are Decreased in Morbid Obesity and Related to Liver FunctionInternational Journal of Molecular Sciences 2024; 25(14): 7549 doi: 10.3390/ijms25147549
3
Fan Zhang, Wenjian Li. Correlation Between Metabolic Dysfunction-Associated Steatotic Liver Disease and the Risk of Urinary Incontinence in Adult WomenInternational Journal of Women's Health 2024; : 1607 doi: 10.2147/IJWH.S489959
4
Fan Zhang, Longgen Liu, Wenjian Li. Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United StatesNutrition Journal 2025; 24(1) doi: 10.1186/s12937-025-01081-0